TX-MAVENIR
14.12.2020 15:02:13 CET | Business Wire | Press release
Mavenir, the industry’s only end-to-end cloud-native network software provider for mobile operators, and Microelectronics Technology Inc. (MTI), a network solutions provider, announced today the general availability of the Evenstar B3 Remote Radio Head (RRH) in collaboration with Facebook Connectivity. The Evenstar B3 RRH will give mobile network operators (MNOs) the ability to accelerate the adoption of Open RAN technology by providing standardized architecture and a modular approach for disaggregated Radio Access Network (RAN) components.
Mavenir and MTI recently completed the end-to-end interoperability testing of the Evenstar B3 RRH and are now lab testing the solution with multiple MNOs around the world. The Evenstar B3 RRH from Mavenir and MTI not only addresses current feature requirements in networks today, but also provides flexibility for future feature upgrades, providing a true Virtualized RAN (vRAN) solution.
Launched earlier this year, the Evenstar program focuses on building general-purpose RAN reference architecture for 4G and 5G networks that are aligned with 3GPP and O-RAN specifications. The Evenstar program also contributes to the Telecom Infra Project (TIP)’s OpenRAN Project Group, working to accelerate the path to commercial deployment of simplified, flexible, disaggregated RAN technologies. RRHs, distribution units (DU), and control unit (CU) software have traditionally been only available as a packaged unit, limiting opportunities to serve suburban and rural locations. By decoupling these components, the Evenstar program enables MNOs to choose best-in-class technology and deploy solutions from an increasing number of technology partners.
“The availability of low cost RRHs based on OpenRAN specifications is key to faster adoption of OpenRAN. We are excited to work with Facebook, TIP and MTI to bring the first 4G/5G OpenRAN-compliant Evenstar radio to market that is generally available for use by the Open RAN community.” said Pardeep Kohli, President & CEO of Mavenir.
“MTI is excited to announce the general availability of the Evenstar RRH. This is a major milestone for MTI and for our partners in the Open RAN ecosystem. We will continue to introduce more products to the Open RAN market and address the needs of different regions.” said Allen Yen, Chairman & CEO of MTI.
The Evenstar B3 RRH is generally available now as part of the Evenstar program, with plans to expand into other Open RAN architectural elements. The Evenstar program will eventually include multiple RRH product SKUs, including FDD B3 (4T4R 4X40W). The RRH architecture is based on O-RAN Alliance Fronthaul specifications based on Split 7.2.
About MTI
Microelectronics Technology Inc. (MTI) is a high-technology company that has specialized in wireless communication product development, manufacturing, and global sales for more than 35 years. Based on core competency in RF/ Microwave, MTI has established a leading position in the fields of Remote Radio Heads, Microwave Radios, Satellite Transceivers and ODUs, Broadband Wireless access products, and Radio Frequency Identification (RFID) readers and modules. With this excellent record of accomplishment, MTI has established valued, long-term partnerships with world-leading partners. MTI now offers a portfolio of products that are O-RAN compliant. For more information, visit: www.mtigroup.com
About Mavenir
Mavenir is the industry's only end-to-end, cloud-native Network Software and Solutions/Systems Integration Provider, focused on accelerating software network transformation for Communications Service Providers (CSPs). Mavenir offers a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging innovations in IMS (VoLTE, VoWiFi, Advanced Messaging (RCS)), Private Networks as well as vEPC, 5G Core and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 120 countries, which serve over 50% of the world’s subscribers.
Mavenir embraces disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. For more information, visit: www.mavenir.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005169/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom